Menopausal hormone therapy and cervical cancer: A current view of the problem
Objective. To carry out a systematic analysis of the results of investigations of whether menopausal hormone therapy (MHT) can be used in patients who have been diagnosed with cervical cancer (CC) and/or completed treatment.Yakushevskaya O.V., Yureneva S.V., Khabas G.N., Protasova A.E.
Material and methods. The article includes the data of foreign articles published in Pubmed and Medline the past 20 years.
Results. This paper presents the results of retrospective studies, the purpose of which was to determine the rate of recurrent CC in women receiving MHT compared with the control group.
Conclusion. On the one hand, menopausal symptoms developing after surgery (after both panhysterectomy and organ-sparing surgery) and radiation with or without systemic (cytostatic) treatments continue to remain relevant to patients who have successfully completed treatment for squamous cell cancer of the cervix. On the other hand, clinicians need to have clinical protocols regulating the basic criteria for prescribing MHT.
Keywords
menopausal hormone therapy
systemic (cytostatic) therapy
cervical cancer
Supplementary Materials
References
1. O’Donnel R.L., Clement K.M., Edmondson R.J. Hormone replacement therapy after treatment for a gynecological malignancy. Curr. Opin. Obstet. Gynecol. 2016; 28(1): 32-41.
2. Юренева С.В., Ильина Л.М., Якушевская О.В. Менопаузальная гормональная терапия в постменопаузе: качество жизни сегодня и в долгосрочной перспективе. Гинекология. 2016; 18(1): 24-9. [Yureneva S.V., Ilina L.M., Yakushevskaya O.V. Menopausal hormone therapy in postmenopause: the quality of life today and in the long term. Ginekologiya. 2016; 18 (1): 24-9. (in Russian)]
3. Baber R., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50.
4. Armeni E., Lambrinoudaki I., Ceausu I., Depypere H., Mueck A., Pérez-López F.R. et al. Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). Maturitas. 2016; 89: 63-72.
5. Каприна А.Д., Старинский В.В., Петрова Г.В., ред. Злокачесвенные новообразования в России в 2014 году (заболеваемость и смертность). М.: МНИОЦ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России; 2016. [Kaprina A.D., Starinsky V.V., Petrova G.V., ed. Malignant neoplasms in Russia in 2014 (morbidity and mortality). Moscow: MNIOTs im. P.A. Gertsena – filial FGBU «NMIRTs» Minzdrava Rossii; 2016. (in Russian)]
6. Хохлова С.В., Коломиец Л.А., Кравец О.А., Крикунова Л.И., Морхов К.Ю., Нечушкина В.М., Новикова Е.Г., Телетаева Г.М., Урманчеева А.Ф., Тюляндина А.С. Практические рекомендации по лекарственному лечению рака шейки матки. Злокачественные опухоли. 2016; 4(Спецвыпуск 6): 147-60. [Khokhlova S.V., Kolomiets L.A., Kravets O.A., Krikunova L.I., Morkhov K.Yu., Nechushkina V.M., Novikova E.G., Teletaeva G.M., Urmancheeva A.F., Tyulyandina A.S. Practical recommendations for the treatment of cervical cancer Zlokachestvennyie opuholi. 2016; 4 (Special Issue 6): 147-60. (in Russian)]
7. Gubbala K., Laios A., Gallos I., Pathiraja P., Haldar K., Ind T. Outcomes of ovarian transposition in gynecological cancers: a systematic review and meta-analysis. J Ovarian Res. 2014; 7: 69.
8. Buekers T.E., Anderson B., Sorosky J.I., Buller R.E. Ovarian function after surgical treatment for cervical cancer. Gynecol. Oncol. 2001; 80(1): 85-8.
9. NCCN. Guidelines Version 1. Cervical Cancer. 2016.
10. Colombo N., Carinelli S., Colombo A., Marini C., Rollo1 D., Sessa C. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012; 23(Suppl. 7): 27-32.
11. Parazzini F., La Vecchia C., Negri E., Franceschi S., Moroni S., Chatenoud L., Bolis G. Case control study of oestrogen replacement therapy and risk of cervical cancer. BMJ. 1997; 315(7100): 85-8.
12. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol. Oncol. 1987; 26(2): 169-77.
13. Hunt K., Vessey M., McPherson K., Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br. J. Obstet. Gynaecol. 1987; 94(7): 620-35.
14. Adami H.O., Persson I., Hoover R., Schairer C., Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int. J. Cancer. 1989; 44(5): 833-9.
15. Persson I., Yuen J., Bergkvist L., Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort. Int. J. Cancer. 1996; 67(3): 327-32.
16. Lacey J.V. Jr., Brinton L.A., Barnes W.A., Gravitt P.E., Greenberg M.D., Hadjimichael O.C. et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol. Oncol. 2000; 77(1): 149-54.
17. Dallenbach-Hellweg G., Poulsen G. Atlas of histopathology of the cervix uteri. Berlin: Springer; 1990.
18. Ibeanu O., Modesitt S.C., Ducie J., von Gruenigen V., Agueh M., Fader A.N. Hormone replacement therapy in gynecologic cancer survivors: Why not? Gynecol. Oncol. 2011; 122(2): 447-54.
19. Jaakkola S., Pukkala E., Lyytinen H.K.,Ylikorkala O. Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer. Int. J. Cancer. 2012; 131(4): Е537-43.
20. Panay N., Hamoda H., Arya R., Savvas M.; British Menopause Society and Women’s Health Concern. The 2013 British Menopause Society and Women’s Health Concern recommendations on hormone replacement therapy. Menopause Int. 2013; 19(2): 59-68.
21. Singh P., Oehler M.K. Hormone replacement after gynaecological cancer. Maturitas. 2010; 65(3): 190-7.
22. Hinds L., Price J. Menopause, hormone replacement and gynaecological cancers. Menopause Int. 2010; 16(2): 89-93.
23. Biliatis I., Thomakos N., Rodolakis A., Akrivos N., Zacharakis D., Antsaklis A. Safety of hormone replacement therapy in gynaecological cancer survivors. J. Obstet. Gynaecol. 2012; 32(4): 321-5.
24. Sjoquist K.M., Martyn J., Edmondson R.J., Friedlander M.L. The role of hormonal therapy in gynecological cancers-current status and future directions. Int. J. Gynecol Cancer. 2011; 21(7): 1328-33.
Received 27.02.2017
Accepted 28.04.2017
About the Authors
Yakushevskaya Oksana Vladimirovna, Ph.D., scientific employee of the department of gynecological endocrinology, Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +79055347208. E-mail: ykushox83@mail.ruYureneva Svetlana Vladimirovna, MD, professor, leading researcher of the department of gynecological endocrinology, Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +79161797400. E-mail: syureneva@gmail.com
Khabas Grigory Nikolaevich, Candidate of Medical Science, Leading Researcher, Head of the Department of Innovative Oncology and Gynecology, Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954388540. E-mail: g_khabas@oparina4.ru
Protasova Anna Eduardovna, MD, Professor, Department of Oncology, Medical Faculty, St. Petersburg State University; Professor of the Department of Obstetrics and Gynecology, V.A. Almazov North-West Research Center. 199034, Russia, St. Petersburg, Universitetskaya nab. 7-9. E-mail: protasova1966@yandex.ru
For citations: Yakushevskaya O.V., Yureneva S.V., Khabas G.N., Protasova A.E. Menopausal hormone therapy and cervical cancer: A current view of the problem. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (11): 148-53. (in Russian)
https://dx.doi.org/10.18565/aig.2017.11.148-153
Similar Articles
